Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolgolimab vs Docetaxel in 2nd-line NSCLC
NCT03288870Phase 3Unknown
- Sponsor
- BIOCAD
- Start
- Sep 2017
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of prolgolimab in non-small cell lung cancer (NSCLC), sponsored by BIOCAD. Status: unknown.
02
Drugs
prolgolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03288870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288870.